Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Ray-Coquard I, et al. Among authors: dufresne a. Cancer Res. 2009 Jul 1;69(13):5383-91. doi: 10.1158/0008-5472.CAN-08-3845. Epub 2009 Jun 23. Cancer Res. 2009. PMID: 19549917 Free PMC article.
Pazopanib for the treatment of soft-tissue sarcoma.
Heudel P, Cassier P, Derbel O, Dufresne A, Meeus P, Thiesse P, Ranchère-Vince D, Blay JY, Ray-Coquard I. Heudel P, et al. Among authors: dufresne a. Clin Pharmacol. 2012;4:65-70. doi: 10.2147/CPAA.S33195. Epub 2012 Oct 26. Clin Pharmacol. 2012. PMID: 23204874 Free PMC article.
[Molecular biology of sarcoma and therapeutic choices].
Dufresne A, Cassier P, Heudel P, Pissaloux D, Wang Q, Blay JY, Ray-Coquard I. Dufresne A, et al. Bull Cancer. 2015 Jan;102(1):6-16. doi: 10.1016/j.bulcan.2014.12.005. Epub 2015 Jan 13. Bull Cancer. 2015. PMID: 25609490 Review. French.
A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial.
Delrieu L, Pérol O, Fervers B, Friedenreich C, Vallance J, Febvey-Combes O, Pérol D, Canada B, Roitmann E, Dufresne A, Bachelot T, Heudel PE, Trédan O, Touillaud M, Pialoux V. Delrieu L, et al. Among authors: dufresne a. JMIR Res Protoc. 2018 Aug 30;7(8):e10487. doi: 10.2196/10487. JMIR Res Protoc. 2018. PMID: 30166274 Free PMC article.
Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancer.
Delrieu L, Vallance JK, Morelle M, Fervers B, Pialoux V, Friedenreich C, Dufresne A, Bachelot T, Heudel PE, Trédan O, Pérol O, Touillaud M. Delrieu L, et al. Among authors: dufresne a. Eur J Cancer Care (Engl). 2020 Jan;29(1):e13169. doi: 10.1111/ecc.13169. Epub 2019 Sep 30. Eur J Cancer Care (Engl). 2020. PMID: 31571315
Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study.
Delrieu L, Pialoux V, Pérol O, Morelle M, Martin A, Friedenreich C, Febvey-Combes O, Pérol D, Belladame E, Clémençon M, Roitmann E, Dufresne A, Bachelot T, Heudel PE, Touillaud M, Trédan O, Fervers B. Delrieu L, et al. Among authors: dufresne a. JMIR Mhealth Uhealth. 2020 Jan 28;8(1):e12306. doi: 10.2196/12306. JMIR Mhealth Uhealth. 2020. PMID: 32012082 Free PMC article.
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.
Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, Cassier P, Eberst L, Steineur MP, Kazes M, Perol M, Michallet AS, Rey P, Erena-Penet AS, Morel A, Brahmi M, Dufresne A, Tredan O, Chvetzoff G, Fayette J, de la Fouchardiere C, Ray-Coquard I, Bachelot T, Saintigny P, Tabutin M, Dupré A, Nicolas-Virelizier E, Belhabri A, Roux PE, Fuhrmann C, Pilleul F, Basle A, Bouhamama A, Galvez C, Herr AL, Gautier J, Chabaud S, Zrounba P, Perol D, Blay JY. Assaad S, et al. Among authors: dufresne a. Eur J Cancer. 2020 Aug;135:251-259. doi: 10.1016/j.ejca.2020.05.028. Epub 2020 Jun 7. Eur J Cancer. 2020. PMID: 32540204 Free PMC article.
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.
Heudel P, Chabaud S, Perol D, Flechon A, Fayette J, Combemale P, Tredan O, Desseigne F, de la Fouchardiere C, Boyle H, Perol M, Bachelot T, Cassier P, Avrillon V, Terret C, Michallet AS, Neidhardt-Berard EM, Nicolas-Virelizier E, Dufresne A, Belhabri A, Brahmi M, Lebras L, Nicolini F, Sarabi M, Rey P, Bonneville-Levard A, Rochefort P, Provensal AM, Eberst L, Assaad S, Swalduz A, Saintigny P, Toussaint P, Guillermin Y, Castets M, Coutzac C, Meeus P, Dupré A, Durand T, Crochet H, Fervers B, Gomez F, Rivoire M, Gregoire V, Claude L, Chassagne-Clement C, Pilleul F, Mognetti T, Russias B, Soubirou JL, Lasset C, Chvetzoff G, Mehlen P, Beaupère S, Zrounba P, Ray-Coquard I, Blay JY. Heudel P, et al. Among authors: dufresne a. ESMO Open. 2021 Feb;6(1):100044. doi: 10.1016/j.esmoop.2020.100044. Epub 2021 Jan 27. ESMO Open. 2021. PMID: 33516148 Free PMC article.
363 results